Imagine bacteria as a lock that has changed its shape so the old keys (antibiotics) no longer fit. This project created a special 'unlocking' tool called ANT3310 that breaks the bacteria's defense, allowing a standard antibiotic to enter and kill the germ. It effectively restores the power of existing medicine against the most dangerous hospital-acquired infections.
Multidrug-resistant Gram-negative bacteria are creating a global health crisis where standard antibiotics no longer work. This leads to high mortality rates and massive economic burdens on healthcare systems.
A combination therapy consisting of the antibiotic meropenem and a proprietary serine-beta-lactamase inhibitor (ANT3310) that restores antibiotic activity against critical priority pathogens.
If you are a pharmaceutical company dealing with a lack of effective antibacterial agents in your pipeline — this project developed the ANT3310 inhibitor that restores meropenem activity against critical priority pathogens. This provides a clear path to a high-value asset for treating hospital-acquired pneumonia.
If you are a hospital network dealing with the high cost of treating ventilator-associated pneumonia and multidrug-resistant infections — this project developed a combination treatment effective against all three WHO critical priority pathogens. This reduces the risk of treatment failure in complicated urinary tract infections.
If you are a biotech firm dealing with the difficulty of bringing antibacterial solutions to market — this project developed a best-in-class serine-beta-lactamase inhibitor. It has already successfully concluded Phase 1 First-in-Human trials as of Q3 2024.
The project expects that ANT3310 will generate over €10bn in sales within 13 years.
The business model is to conduct three clinical trials and then out-license ANT3310 to a pharmaceutical partner.
The project has moved beyond pre-clinical efficacy and successfully concluded a Phase 1 First-in-Human trial in Q3 2024.
Market approval is expected by 2029.
In September 2024, the FDA endorsed the program, and Phase 1 trials for safety and pharmacokinetics were completed in Q3 2024.
The project is led by a single French SME, ANTABIO, with a 100% industry ratio. This lean structure allows for rapid decision-making and direct control over the proprietary ANT3310 asset, focusing entirely on clinical validation and the eventual out-licensing to a larger pharmaceutical partner.
Contact ANTABIO SAS in France regarding the MEM-ANT3310 licensing opportunities.
Contact us to facilitate a partnership between your pharma portfolio and ANTABIO.
